A Retrospective Pharmacoeconomic Study of Lung Cancer

Lung Cancer Clinical Trial

Official title:

A Retrospective Pharmacoeconomic Study of Lung Cancer in Wan-Fang Hospital

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01140958
• Other study ID #: Pharmacoeconomic-01
• Status: Active, not recruiting
• Phase: N/A
• First received: June 8, 2010
• Last updated: June 9, 2010
• Start date: March 2008
• Est. completion date: November 2010

Study information

• Verified date: June 2010
• Source: Taipei Medical University WanFang Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

Lung cancer is the No. cause of cancer death in Taiwan. Yet most of lung cancer are diagnosed at late stage, not amenable to surgical resection. With the introduction of new targeted agents, such as EGFR tyrosine kinase inhibitors and the identification of EGFR mutations, lung cancer management has markedly changed in recent years. However, these new agents are costly and their payment is restricted in certain situations defined National Insurance Agency. Therefore, using databases from National Insurance Agency might not be able to reflect the exact impact on pharmacoeconomics. In this study, the investigators will analyze the data from a tertiary medical center, where all the costs including insurance reimbursement, co-payment, and payment not covered by insurance. The investigators will also compare with the investigators results with national database to analyze the cost benefit of these new agents on lung cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 91
• Est. completion date: November 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• lung cancer patients in WanFang Hospital

Exclusion Criteria:

• non

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University WanFang Hospital